The Intego database: background, methods and basic results of a Flemish general practice-based continuous morbidity registration project by Truyers, Carla et al.
Truyers et al. BMC Medical Informatics and Decision Making 2014, 14:48
http://www.biomedcentral.com/1472-6947/14/48RESEARCH ARTICLE Open AccessThe Intego database: background, methods and
basic results of a Flemish general practice-based
continuous morbidity registration project
Carla Truyers1*, Geert Goderis1, Harrie Dewitte1, Marjan vanden Akker2 and Frank Buntinx2Abstract
Background: Intego is the only operational computerized morbidity registration network in Belgium based on
general practice data. Intego collects data from over 90 general practitioners. All the information is routinely
collected in the electronic health record during daily practice.
Methods: In this article we describe the design and methods used within the Intego network together with some
of its basic results. The collected data, the quality control procedures, the ethical-legal aspects and the statistical
procedures are discussed.
Results: Intego contains longitudinal information on 285 357 different patients, corresponding to over 2.3% of
the Flemish population representative in terms of age and sex. More than 3 million diagnoses, 12 million drug
prescriptions and 29 million laboratory tests have been recorded.
Conclusions: Intego enables us to present and compare data on health parameters, incidence and prevalence rates,
laboratory results, and prescribed drugs for all relevant subgroups on a routine basis and is unique in Belgium.
Keywords: Morbidity registration network, General practice, Methodology, Quality assessmentBackground
General practioners such as William Pickles in the UK
and Frans Huyghen in the Netherlands founded general
practice-based epidemiology in the last century. They
kept meticulous notes about patients’ disease histories
and other relevant information. They realised that gen-
eral practice provided them with the opportunity to
study morbidity in an unselected population over many
decades [1].
Computerized patient records in general practice brought
a significant change. Databases could be created with longi-
tudinal data covering millions of patient-years. It became
easier to study health parameters, diagnoses, laboratory re-
sults, prescribed drugs and their interrelations. Many net-
works were established each with their own accents.
Intego is one of those general practice databases with in-
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unless otherwise stated.covering 285 thousand individual patients and over two
million patient-years. All information is routinely collected
and derived from the electronic health record during daily
practice. The network was founded in 1994 and data is
sent to a central database at regular intervals. Its initial
aim was to collect incidence rates of diagnoses presented
to the general practitioner. Almost half of the Belgian gen-
eral practitioners work in solo-practices, without add-
itional staff and rather demand driven. Theoretically all
patients can directly contact a specialist, although most
patients will be referred to them by a general practitioner
[2]. Specialists should inform the general practitioner by
means of a digital letter. Patients are not registered in a
particular practice, unlike in the Netherlands, where the
general practitioner serves as a gatekeeper, but tend to
visit the same practice over time.
The gathered information is used as a basis for teach-
ing, quality improvement interventions, and research, as
well as for policy making by both physicians’ organisa-
tions and governmental bodies. Over the years, the net-
work’s aims broadened and now also include the naturalLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Truyers et al. BMC Medical Informatics and Decision Making 2014, 14:48 Page 2 of 9
http://www.biomedcentral.com/1472-6947/14/48history of diseases, etiological and prognostic research,
evaluation of population-based interventions with re-
spect to prevention and quality improvement and rela-
tions between diagnostic categories, laboratory results
and prescribed drugs. The network is mainly funded by
the Health ministry of the Flemish government. Ad hoc
research projects serve as an additional funding source.
In this paper we describe the design and methods
used within the Intego network together with some of
its basic results.
Methods
Data collection
At the start of the Intego-project it was decided to use
the medical electronic health record - Medidoc® - which
is one of the few existing packages in Belgium allowing
routine input of coded diagnoses and other coded data.
All data are recorded by the general practitioner using
keywords in a predetermined field in the electronic
health record. Each of the 67500 keywords is associated
with a unique program-specific internal code and can be
linked to classifications as ICPC-2, ICD-10 and ATC-
DDD (Table 1).
When a general practitioner agrees to participate a
software module copies the data from the general practi-
tioner into a text file. For apparent privacy reasons each
patient is assigned a random number. This file is then
encrypted and sent to an independent trusted third party
that recodes the data and subsequently sends it to the
department of general practice of the KU Leuven where
it is stored into the central database. The trusted third
party procedure has been in place since 2012.
Quality of the data
Selection procedure
General practitioners willing to participate in Intego
have to pass three general quality criteria. First, the
average number of new diagnoses per patient per year
should be higher than one. This number was chosen
based on a graphical presentation of the average number
of new dagnoses per year, which showed a clear cutpoint
at one. This number corresponds with what was found
in the Nijmegen Continuous Morbidity Registration [2].
Secondly, the percentage of diagnoses recorded without
using keywords should be less than five percent. Finally,
these parameters must remain stable for at least three
years. With these criteria, in particular the first one, weTable 1 Notation of diagnoses in Medidoc
Free text Keyword Progra
Complex fracture of leg
Fracture tibia diaphysis closed → Q
Qintend to minimize the risk of recording bias, where general
practitioners only register certain, e.g. serious, diagnoses.Collected data
The following data are copied from the general practi-
tioner’s electronic health record into the Intego database:
year of birth, gender, the years that the patient contacted
the practice, diagnoses, drug prescriptions, laboratory re-
sults, some biomedical parameters such as blood pres-
sure, height, weight, smoking status and mortality. Other
lifestyle information, such as nutrition, is not recorded.
Once the data are in the database a check is performed
to see whether the data are as correct and complete as
possible [3-5]. With regard to registration networks, cor-
rectness refers to whether a patient with a diagnosis in
the electronic health record also suffers from that par-
ticular disease. Completeness refers to whether the rec-
ord of a patient with a certain disease contains that
diagnosis. Validation of a network can be performed by
means of external (comparison with other registries or
studies as a measure of completeness) and internal
methods (tracers as a measure of correctness). Tracers
are known relationships between background character-
istics, gender, age, laboratory test results or medication
and disease: e.g. patients receiving insulin treatment
should also have a registered diagnosis for diabetes.
External validation of the Intego database has been ex-
amined by means of national and international compari-
sons. Nationally, overall cancer incidence was compared
to the Limburg Cancer Registry (LIKAR). Our incidence
rates of influenza and acute respiratory illness were com-
pared to the European Influenza Surveillance Scheme,
EISN [6]. Data found in Intego are routinely compared to
the Tweede nationale studie, studying morbidity and care
in Dutch general practice [7]. Serious infections in chil-
dren were compared to data from other networks [8].
Several diseases were compared to the Dutch CMR
(Nijmegen) and RNH (Maastricht).
Other validation methods are either irrelevant in these
systems (for example comparison with paperbased data)
or impossible (for example merging with other databases
such as cancer registries) because patients cannot be
identified due to privacy reasons. The feasibility of link-
ing patient data from other sources (e.g., hospital) with
Intego data by means of a trusted third party is currently
under study.m code ICPC-code ICD-9-CMcode ICD-10 code
→ L73
82320
82320 → L73 → 823.20 → S82.20
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Basic analysis
Intego can provide data about incidences and preva-
lences of diseases, distribution of risk factors, time
trends, age- and gender differences and drug use.
Incidence is calculated as the number of new cases of
disease divided by the person-time magnitude [9]. Inci-
dence rates can be provided for the total population, or
stratified by age group and/or gender or some other ad
hoc defined subgroup and can be standardized for the
Flemish, Belgian, European or World population. The
denominator is the yearly contact group (YCG), patients
which visit the practice at least once in a given year or
the practice population, all patients in a practice, con-
sisting of the YCG plus the group which does not visit
their general practitioner in a given period. This last
group is estimated from all non-profit health insurance
agencies, which includes complete data on all reim-
bursed medical and paramedical acts, age, gender and
residence as well as the total insured population. A
yearly correction factor is calculated, to estimate the per-
centage of patients consulting a general practitioner by
age group, gender and region and hence the practice
population.
The prevalence of a population is the proportion of
the population with the disease at a specified time. Un-
like incidence rates, which focus on new events, preva-
lence focuses on existing states. Because of the design of
Intego (no episode registration and no recording of cure)
prevalence rates can only be calculated on incurable
chronic diseases, such as diabetes.
Gender differences are usually expressed as sex ratios,
which represent the incidences in female to male rate
(or vice versa). Age is divided into Wonca-age groups or
analysed as a continuous variable.
Identifying rising and declining trends in disease and
other medical data is an important part of epidemiology.
Environmental changes, prevention, public health action,
behavioral changes etc. can all result in disease incidence
changes. The Intego database can provide data from
1994 until now and can study time trends or seasonal
effects in diseases using standard time series analysis
techniques [10], [6].
Medication is coded according to the Belgian coding
system CNK (national codes) which can easily be trans-
lated into the ATC-DDD format. These data can be
used for pharmacovigilance and pharmacoepidemiologi-
cal purposes.
Design
Many study designs can be used, such as incidence stud-
ies, retrospective cohort studies, case‐control studies and
cross‐sectional designs in an unselected patient group
or subgroup. For each individual study, the samplepopulation is chosen according to specific inclusion and
exclusion criteria depending on the aim of the study.
Statistics and data analysis
When a research question is formulated, and the use of
morbidity registration data is deemed relevant to answer
this question, a protocol is written, data is collected, sta-
tistically analyzed and results are summarized. There are
many approaches for making inferences from observa-
tional studies, some focusing on the data collection
(design), others on the statistical analyses. However, even
with the best designs, observational studies do not auto-
matically control for selection bias. Therefore matching,
standardization, stratification and/or covariance adjust-
ment are needed [11]. The purpose of these techniques
is to create index and control groups eliminating bias as
much as possible. Matching and covariate adjustment
are most often used. For covariate adjustment the vari-
ables that should be balanced (mostly at least age, gen-
der and practice) are put explicitly in the statistical
model and this way adjusted for. This method could
however produce biased results if there is an additional
imbalance in background variables which are not stated
in the model (e.g. smoking or other confounders).
Matching is based on at least gender, age (+/− 5 years)
and within practices and constitutes most likely of a 5 to
1 ratio [12]. Standardization can be performed with any
relevant population, including one of the comparison
groups. Most frequently used are the standard Flemish
or European populations. The latter is most popular
in cancer related epidemiological studies [13]. Statistical
techniques which are often used are ordinary least squares
regression, logistical regression, and survival analysis.
An internal manual for analyzing repeatedly intro-
duced data, such as laboratory (e.g. HbA1c) or clinical
data (e.g. blood pressure) was constructed in order to
standardize analysis procedures disposable for all re-
searchers using the database. For instance, in some lon-
gitudinal analyses, we aggregate individual values on a
yearly basis. For LDL-cholesterol and HbA1c, we take
the last value of each year, but for creatinine e.g. we take
the average value of the last two measurements of each
year in order to account for the important within subject
variability of this variable [14].
Legal ethical aspects
At the start of the project a proposal was submitted to
the Belgian Privacy Commission. No comments were
provided by them. The procedures were also reviewed
and approved by the ethical review board of the medical
school of the Katholieke Universiteit Leuven [15]. More
recently, the Sectoral Committee ‘Health’ of the Belgian
privacy commission thoroughly reviewed our procedures
and asked for the use of a third trusted party for additional
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of a scientific and ethical review board. These boards con-
sist of researchers, both from our department and from
other universities, Intego registering practitioners, a non-
medical reviewer and an ethicist and lawyer. They assess
whether the questions are ethically correct (Ethics Board)
and scientifically sound (Scientific Board). They have an
advisory function, comparable to a Data Safety Monitoring
Board in clinical trials. After these improvements our pro-
cedures are compliant with the law confirmed by decision
nr. 13.026 of March 19th, 2013.
Results
General practitioners
Between 1999 and 2012, 144 different practices provided
their data. Based on the criteria specified above, 51 prac-
tices (representing 95 general practitioners) were se-
lected for inclusion in the database. The practices are
spread throughout Flanders, but are not selected to be
representative for the Flemish general practitioners. The
general practitioners in the project represent slightly
fewer women and are slightly older than the Flemish
general practitioners overall.
Patients
The database contains information on 285 357 different
patients, with 2 million patient-years for 1994–2011. In
the year 2011, 115 303 of these patients contacted their
general practitioner. This corresponds to an estimated
practice population of 143 495, which is 2.3% of the
Flemish population. The Intego-population is represen-
tative for the Flemish population in terms of age and
sex (Figure 1). The largest difference is 3.2% in the
age group 25–44 years. In all these patients 3 millionFigure 1 The Flemish population and the population of the Intego-dadiagnoses, 12 million drug prescriptions and 29 million
laboratory tests have been recorded.
Data
The proportion of new diagnoses in each ICPC-chapter
is stable over the years (Figure 2) with respiratory disor-
ders making up the vast majority of diagnoses (33% of
all new diagnoses in 2011). These are followed by mus-
culoskeletal disorders with 18%, gastro-intestinal disor-
ders with 13% and skin diseases with 10%. These four
chapters together constitute 74% of all new diagnoses.
The 13 remaining chapters each represent less than 4%
of all new diagnoses. These proportions correspond well
to the 20 most common diagnoses (Table 2), with infec-
tions of the respiratory tract and diseases of the loco-
motor apparatus at the top of the list.
A typical analysis dataset contains event dates for all
variables under study and patient characteristics (e.g.
gender and year of birth).
Basic incidence rates are calculated by 1000 or 100,000
person-years and stratified by gender. For example the
incidence rate of malignant melonoma is 8/100,000
patient-years overall, and 6.5 and 9.7/100,000 patient-
years for males and females. In many cases results are
also presented by age groups. Prevalence rates can be
calculated for chronic conditions.
Because all prescriptions are registered in the electronic
health record these data can be used for studies on drug
prescriptions (e.g. the relationship between atypical anti-
psychotic use and subsequent risk of diabetes) [16].
Several international peer reviewed articles have been
published using data from the Intego database. For
example, Intego produced antibiotic prescribing indica-
tor values. These values reveal huge opportunities totabase by age.
Figure 2 Proportion of new diagnoses per ICPC-chapter.
Table 2 The 20 most frequent new diagnoses in 2011
Female Male
ICPC Code Diagnosis Total number ‰ ICPC Code Diagnosis Total number ‰
R74 Upper respiratory infection acute 40391 233 R74 Upper respiratory infection acute 36248 226
R80 Influenza 13016 75 R80 Influenza 13151 82
D73 Gastroenteritis presumed infection 12305 71 D73 Gastroenteritis presumed infection 12060 75
R78 Acute bronchitis/bronchiolitis 10288 59 R78 Acute bronchitis/bronchiolitis 10230 64
U71 Cystitis/urinary infection other 8080 47 L03 Low back symptom/complaint 7345 46
L03 Low back symptom/complaint 7427 43 L87 Bursitis/tendinitis/synovitis nos 5583 35
L83 Neck syndrome 6987 40 S16 Bruise/contusion 4702 29
R75 Sinusitis acute/chronic 6454 37 H71 Acute otitis media/myringitis 4409 28
L87 Bursitis/tendinitis/synovitis nos 5992 35 L83 Neck syndrome 4148 26
H71 Acute otitis media/myringitis 4434 26 R75 Sinusitis acute/chronic 3699 23
R76 Tonsillitis acute 4225 24 R76 Tonsillitis acute 3647 23
S16 Bruise/contusion 4166 24 R77 Laryngitis/tracheitis acute 2803 17
D87 Stomach function disorder 3987 23 S74 Dermatophytosis 2615 16
R77 Laryngitis/tracheitis acute 3786 22 D87 Stomach function disorder 2547 16
L92 Shoulder syndrome 3002 17 L92 Shoulder syndrome 2519 16
R05 Cough 2526 15 R05 Cough 2242 14
L86 Back syndrome with radiating pain 2450 14 D84 Oesophagus disease 2053 13
D84 Oesophagus disease 2423 14 L86 Back syndrome with radiating pain 2050 13
A04 Weakness/tiredness general 2373 14 K86 Hypertension uncomplicated 1873 12
S74 Dermatophytosis 2183 13 S18 Laceration/cut 1762 11
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the prescription of recommended antibiotics [17]. Next
to this, it was found that chronic kidney disease is highly
prevalent in patients with type 2 diabetes mellitus and
that only a minority of patients evolve into severe de-
cline which is associated with younger age, male gender,
a year-to-year decline of >10 mL/min and manageable
factors such as blood pressure, blood glucose, associated
drugs prescriptions including statin therapy [14]. An-
other example is low back pain (LBP). Most studies on
comorbidity in LBP have been conducted in specialized
settings with the use of self-reports. Low back pain is
one of the most frequent diagnoses in general practice.
Striking is the higher frequency of common self-limiting
diseases in patients with a diagnosis of LBP during the
same year [18]. In another study a moderate significant
association between herpes zoster and subsequent can-
cer risk in women older than 65 years was found, with-
out any influence of antiviral therapy. No association
was found with herpes simplex [19].
Quality of the data
We continuously compare our results with results from
other registries and groups. Up to now, there is no gold
standard to measure the quality of registered data. Regis-
tering practitioners have to pass the above mentioned
quality criteria. It is however not clear to what extent
these criteria really increase the quality of gathered data.
It is also unclear whether supplemental criteria can be
useful to increase the quality. External validation of the
data with other registries compares similar databases
which may suffer from the same biases. A comparison
with registers such as the NIVEL primary care database
or IPCI database in the Netherlands or the Health Im-
provement Network (THIN) database in the UK might
be interesting for this purpose, since they use both
coded and free text data. All are large longitudinal gen-
eral practice research databases which are based on
routinely collected data of a non selected population.
Comparison to data from databases where all general
practitioners who want to participate can participate in
Intego which selects their general practitioners based on
stringent registration quality criteria might provide use-
ful insights to our quality criteria.
With regard to cancer incidences, Intego and LIKAR
respectively registered 3.83 and 3.63 cases of invasive
cancers (exclusion of basal cell carcinoma) per 1,000 pa-
tient years [20]. Incidences of melanoma (8 versus 8.55
/100,000 patient years), lung (12 and 79 versus 15 and
79/100,000 patient years for females and males) and cer-
vical cancer (9 versus 9.13 /100,000 patient years) were
also very comparable [21,22]. Comparisons on transient
ischemic attacks (TIA) and stroke were performed with
the general practice sentinel network (Belgian ScientificInstitute for Public Health), resulting in comparable inci-
dences for stroke and higher incidences for TIA in
Intego (1.93 versus 1.73 for stroke and 0.89 versus 1.29
/1,000 patient years for TIA) [23]. In preparation of the
H1N1 vaccination campaign the incidence of Guillain
Barré was examined by comparing the number regis-
tered in the database for the most recent years and num-
bers based on recollection by the general practitioners,
assuming every general practitioner remembers the cases
in his/her practice because of its low incidence and its
dramatic clinical picture. Both were in very high agree-
ment, meaning around 1/100,000 patient years and
higher than a specialist (neurologists) registration. Com-
parison with the EISN showed high agreement with
regard to Influenza like illness and acute respiratory in-
fections [6].
The yearly incidence of serious infections in children
aged 0 – 4 years in the Continuous Morbidity Registra-
tion (CMR) is 27–30/1,000 patients, 18.3 in the Dutch
Transition project, 18.1 in Intego and 15.7 in the Weekly
Returns Service (the latter is based on children from
1–4 years old) [8]. Several comparisons with CMR and
RNH resulted in similarities and differences but for none
of the networks a specific direction was found with
regard to the differences. The eHID project, with the
objective to investigate the operational features of net-
works providing epidemiological information based on
the extraction of routinely collected health related data in
order to make recommendations on best recording prac-
tices, compared disease frequency in several European
member states. The Intego data were comparable to other
networks [24].
Internal validation can be performed using tracers. For
diabetes and anti-diabetics 88% of the people who were
prescribed anti-diabetics (ATC, A10A, A10B and A10X)
also had a diabetes diagnosis. With regard to dementia
(ATC, N06DA), migraine (ATC, N02CC) and Parkinson
(ATC, N04A and N04B), associations were lower, re-
spectively 52%, 69% and 36%. Quality improvement pro-
jects are currently ongoing to study these results.
Discussion
Strenghts
Computerisation provides relatively inexpensive and easy
access to large volumes of data. They are population
based and can quickly produce large samples of patients.
Because of the longitudinal nature of the data, many re-
search questions can be answered in a more time and
cost effective manner compared to other study designs
(e.g. newly set up cohort studies).
The most frequently used design is the retrospective
cohort design which enables researchers to analyze a
large amount of data collected and carefully stored in
the past, while analyzing them using a cohort design.
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lected in tempero non suspecto, without any hindsight
of the objectives of the actual study and avoiding the
main risks of bias in prospective study designs, especially
selection and recall bias. Thus, the retrospective design
guarantees that the measurement of predictor variables
was not biased by knowledge of which subjects had the
outcome of interest. In a prospective design, knowledge
of exposure status may bias classification of the out-
come. Also, in a prospective design, being in the study
may alter participant’s behavior. Since data in a registry
are routinely collected, this inclusion bias does not count
for retrospective study designs. Compared to a case–
control design, an advantage of the retrospective cohort
design is that all of the subjects who developed the out-
come (cases) and all those who did not (control) come
from the same population.
A major strength of these types of cohort studies in
general is the possibility to study multiple exposures and
multiple outcomes in one cohort. Even rare exposures
can be studied. The combined effect of multiple expo-
sures on disease risk can be determined. Hypothesis gen-
eration is another benefit of cohort studies considered as
a way to pick up associations between many exposures
and outcomes. Yet because of lack of randomization, co-
hort studies do not permit conclusions about causality.
Several underlying etiological hypotheses can be gener-
ated, to be tested in other confirmatory studies.
Deckers et al. formulated minimal criteria for a pri-
mary care network [25]. Computerisation provides rela-
tively inexpensive and easy access to large volumes of
data. A sufficient sample size is advised to be about 1%
of the population, which allows the study of common
diseases. Increasing the sample size much more will lead
to an increased workload, but is not expected to result
in additional information. Intego covers more than 2% of
the Flemish population, highly representative for age and
gender. Data on age is collected on a continuous scale and
can be divided into as many age groups as needed. Data
from the previous registration year are collected in the
first half of the year. Although data are not collected on a
weekly basis, they can be reconstructed in retrospect to
obtain weekly, monthly or even daily information.
Because Intego is based on routinely collected data
and the study population is selected with broader inclu-
sion and less exclusion criteria compared to an RCT, its
results may be more generalizable to clinical practice.
Weaknesses
Some variables, which may be important confounders in
public health research are not measured (occupation,
employment, and socioeconomic status), measured im-
precisely, or even unknown, such as smoking or mortal-
ity, which is only registered partially. Information fromspecialists as well as events that occur in hospital may not
be fully captured in the electronic health record. Over the
counter medications and treatments given in hospital are
not readily available. Exposure status (e.g. onset of treat-
ment, exact year of diagnosis) may be missed because it
has occurred prior to start of the registration.
The most ill can die, others can be lost to follow-up
because they moved. This will bias the results when se-
lective follow-up rates differ between index and refer-
ence group. Loss to follow-up can be related to future
outcome. The Healthy Survivor Effect (HSE) can be de-
scribed as a continuing selection process in the cohort
due to survival or maintenance of the healthiest individ-
uals, whereas survival/maintenance process may differ
amongst the selected groups (e.g. diabetes or not). The
study will include only patients remaining in the system,
a survivor (healthier) population. HSE can lead to lower
than expected outcomes, can interact with exposure vs.
outcome associations between groups (e.g. statin effect
in longitudinal design on elderly diabetic patients with
and without CKD). When there is no exposure-disease
relationship, higher cumulative exposure appears pro-
tective of health. The effects of healthy patient effect
biases may vary by gender, race/ethnicity, social class,
work status, age at inclusion, length of follow-up or
cause of mortality/morbidity.
Differential misclassification can lead to an overesti-
mation or underestimation of the effect between expos-
ure and outcome. Classification of individuals (exposure
or outcome status) can also be affected by changes in
diagnostic procedures.
Intego is based on routinely collected data. Does the
general practitioner make a correct diagnosis or assess-
ment? This refers to the discussion about diagnosis
(cough, cold,…) in primary care, but also to the problem
of episode registration and changing diagnoses (ex. Myco-
plasma pn. Infection). Criteria based diagnoses are more
accurate than symptom based diagnoses. Second, has the
diagnosis/assessment been correctly coded in the elec-
tronic health record? This question refers to the sensitivity
(or completeness) and the positive predictive value (or
correctness) of electronic health record -based data [26].
Although the patient population is representative for the
Flemish population, registering general practitioners are
not representative for the general practictioner population.
It is a selected group of high quality registering practi-
tioners which use a specific electronic health record. This
selection bias of general practitioners could eventually
have an influence on some process parameters in the
follow-up of patients.
Difficulties arise with tracers, when some drugs are
prescribed for other conditions as well. For example
anti-epileptics are also prescribed for chronic pain. Also
a general practitioner might have a very specific reason
Truyers et al. BMC Medical Informatics and Decision Making 2014, 14:48 Page 8 of 9
http://www.biomedcentral.com/1472-6947/14/48for describing a specific drug to a specific person. The
lower associations between dementia, migraine and
Parkinson with their tracer medications probably were
caused by this lack of specificity.Future
In the near future, large databases with all kinds of infor-
mation will be widely available. Some of these registries
will contain data of almost the entire population of a
country or a region. This is a challenging situation for
the existing databases collecting data from a smaller
sample population. We will have to consider redefining
our strategic goals, methods and procedures.
The option of collecting either blood or buccal smear
samples of patients in Intego is being explored [27].
Together with background characteristics and a full in-
ventory of recorded morbidity, laboratory results and
prescribed drugs, this would enable research on gene-
environment and pharmaco-genetic interactions. This
can only be performed after strict informed consent and
with the agreement of the ethical review board, the na-
tional privacy authorities, and the Flemish authorities
supervising the Flemish Biobank activities.
We will continue to explicitly structure quality proce-
dures with training and coaching, introduce criteria for
diagnosis (for example GOLD criteria for COPD classifi-
cation) and list missing data for possible confounders,
such as smoking and SES. We will check the validity of
our 3 existing quality criteria and continue to work out
and implement internal and external validation proce-
dures. We are convinced that this procedure will pro-
cure a quality label enabling small registries like Intego
to occur as a gold standard for large databases with a lot
of data often extracted from ‘bad’ registrators.
Finally, registries like Intego with a stable group of
practicising general practitioners also offers possibilities
for targeted, experimental, randomized trials.Conclusion
With 95 general practitioners and data covering over
two million patient-years, Intego certainly is not one of
the largest general practice based computerized morbid-
ity registries in the world. Nevertheless, the database en-
ables us to present and compare data on background
information, incidence and prevalence rates, laboratory
results, and prescribed drugs for all relevant subgroups
on a routine basis and is unique in Belgium. This results
from two basic requirements: a group of dedicated gen-
eral practitioners keeping high quality patient records
using highly structured software and a procedure that
does not require them to do anything special, additional
to this record keeping.Competing interests
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